Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07543380 RSVpreF Respiratory Syncytial Virus Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07543380 RSVpreF Respiratory Syncytial Virus Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07543380 clinical trial report covering RSVpreF, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07540988 Nerandomilast Idiopathic Pulmonary Fibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07540988 Nerandomilast Idiopathic Pulmonary Fibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07540988 clinical trial report covering Nerandomilast, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07541079 Giredestrant ER-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07541079 Giredestrant ER-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07541079 clinical trial report covering Giredestrant, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07543224 RSS0393 Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07543224 RSS0393 Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07543224 clinical trial report covering RSS0393, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07541170 Divarasib KRAS G12C mutant Non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07541170 Divarasib KRAS G12C mutant Non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07541170 clinical trial report covering Divarasib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07545395 Armocibart Hemophilia B Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07545395 Armocibart Hemophilia B Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07545395 clinical trial report covering Armocibart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07546500 Azenosertib Ovarian Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07546500 Azenosertib Ovarian Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07546500 clinical trial report covering Azenosertib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07546487 Comekibart Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07546487 Comekibart Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07546487 clinical trial report covering Comekibart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07543536 Megestrol Acetate Fatigue Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07543536 Megestrol Acetate Fatigue Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07543536 clinical trial report covering Megestrol Acetate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
JPRN-jRCT2071260011 Efgartigimod/Hyaluronidase Graves Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
JPRN-jRCT2071260011 Efgartigimod/Hyaluronidase Graves Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
JPRN-jRCT2071260011 clinical trial report covering Efgartigimod/Hyaluronidase, Phase 3, endpoints, sponsor, geography, readout timing and development white
Read →
NCT07557680 Dexmedetomidine Hydrochloride Anesthesia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07557680 Dexmedetomidine Hydrochloride Anesthesia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07557680 clinical trial report covering Dexmedetomidine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white spac
Read →
NCT07545460 Trastuzumab Brengitecan Recurrent ovarian cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07545460 Trastuzumab Brengitecan Recurrent ovarian cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07545460 clinical trial report covering Trastuzumab Brengitecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →